WEBINAR: Phase 3 Study of GTX-102

The Phase 3 Efficacy and Safety Study of GTX-102 (ASO) in Pediatrics, sponsored by Ultragenyx, is now listed on ClinicalTrials.gov.

ASF and FAST will host a webinar about the trial, named Aspire, with the Ultragenyx team.

Registration is required. 

Join us October 23 at 1pm EST.